Navigation Links
OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
Date:8/30/2007

Private offering provides new funding as OncoVista, Inc. takes steps

towards public reporting status.

SAN ANTONIO, Aug. 30 /PRNewswire/ -- OncoVista, Inc., a biopharmaceutical company engaged in the development and commercialization of targeted cancer therapies with improved efficacy and reduced toxicity, announced the successful completion of a private placement offering and its acquisition of a control position in a public reporting shell company.

OncoVista completed the private sale of 970,712 units of common stock and warrants to new and existing investors raising approximately $6.8 million in gross proceeds. Participants in the offering included Wexford Capital LLC, CAMOFI Master LDC, Bristol Investment Fund, Ltd., as well as other select institutional and qualified investors. Maxim Group, LLC acted as the company's exclusive placement agent in the offering. Contemporaneously with the closing, OncoVista acquired a control position in Aviation Upgrade Technologies, Inc., a Nevada corporation (OTC Bulletin Board: AVUG) and transferred the former operating subsidiary to its former chief executive officer.

"The closing of our financing and our acquisition of a public reporting company in preparation for our becoming a publicly-traded company marks a very exciting and important milestone in OncoVista's history," said Alexander L. Weis, Ph.D., Chairman of the Board of Directors, President and Chief Executive Officer of OncoVista, Inc. "Targeted oncology therapy is an attractive and growing business segment, and our ability to access the public capital market is a tremendous opportunity for further growth of OncoVista," Dr. Weis said.

About OncoVista, Inc.

A biopharmaceutical company engaged in the development and commercialization of targeted cancer therapies both through the acquisition of rights to technologies and drugs from others and through the development of proprietary products. OncoVista intends t
'/>"/>

SOURCE OncoVista, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. NimbleGen closes $8.2m venture round, bringing total to $50m
2. BoneCare doubles options and profits as fiscal year closes
3. DEMO 2003 Closes with Focus on Collaboration and Communication
4. Venture Investors early-stage fund grows to $115 million
5. Two convicted of selling $6 million in counterfeit Rockwell software on eBay
6. NimbleGen to discontinue IPO after Roches $272.5 million acquisition
7. TomoTherapy raises $223 million in IPO
8. Fiserv reports $113.5 million in Q1 profit
9. Investors raise $25 million for biodiesel plant
10. Grow Milwaukee includes millions for tech funding
11. Mirus Bio, Pfizer enter multimillion-dollar research agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 2015  BioClinica®, Inc., a leading specialty ... announced that clinical trial professionals representing 20 ... annual European User Conference in ... use of its eClinical technologies to overcome ... the Microsoft Office-Smart OnPoint CTMS; Express EDC; ...
(Date:3/4/2015)... 2015 Lancée par ... en décembre 2011, l,étude collaborative française ... qui compare   l es microsphères en ... dans le carcinome hépatocellulaire avancé, a recruté plus ... avancé   ; les résultats sont attendus fin ...
(Date:3/3/2015)... 3, 2015 NASA astronaut Scott Kelly , ... to spend a year living and working on the International ... 5:30 to 7 a.m. EDT Monday, March 9. ... he completes the final weeks of his training. The interviews ... NASA Television highlighting his mission training and previous spaceflights. ...
(Date:3/3/2015)... 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... and Chief Executive Officer of Neurocrine Biosciences, will be ... The live presentation takes place on ... presentation will be webcast and may be accessed on ... Listeners are encouraged to visit the website approximately ...
Breaking Biology Technology:BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 2Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 5Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 6NASA Astronaut Scott Kelly Available for Interviews before One-Year Space Station Mission 2
... CAPE CORAL, Fla., Nov. 2, 2011 Nature,s Bioceuticals, a ... News ) announced that it has reached an agreement in ... life changing results for hundreds of millions of people worldwide ... agreement will be executed in the coming week, at which ...
... rise, but solar cells are only as efficient as ... of a new professor at Northwestern University,s McCormick School ... new material that absorbs a wide range of wavelengths ... solar technology. A paper describing the findings, "Broadband ...
... Nov. 2, 2011 Advanced BioMedical Technologies Inc. (OTCQB:ABMT), ... is pleased to announce the formation of its scientific ... distinguished physicians and scientists. The combined expertise of the ... strategic input as the Company continues to develop its ...
Cached Biology Technology:Nature's Bioceuticals Close to Finalizing Strategic Transaction in One of the Largest Drug Markets 2Nature's Bioceuticals Close to Finalizing Strategic Transaction in One of the Largest Drug Markets 3Solar power could get boost from new light absorption design 2Advanced BioMedical Technologies Inc. Announces Formation of Scientific Advisory Board 2Advanced BioMedical Technologies Inc. Announces Formation of Scientific Advisory Board 3Advanced BioMedical Technologies Inc. Announces Formation of Scientific Advisory Board 4Advanced BioMedical Technologies Inc. Announces Formation of Scientific Advisory Board 5Advanced BioMedical Technologies Inc. Announces Formation of Scientific Advisory Board 6Advanced BioMedical Technologies Inc. Announces Formation of Scientific Advisory Board 7
(Date:2/5/2015)... Jan. 28, 2015 Research and Markets ... of the "Global Biometrics Market (2014-2020): Market ... Countries " report to their offering. , ... Asia-Pacific is anticipated to overtake ... to increasing government spending towards IT security, government ...
(Date:1/22/2015)... Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to inform ... State of Washington,s Department of Licensing, in the ... issuance system for driver,s licenses and identification cards to its ... development will start in January 2015, with enrollment and card ...
(Date:1/22/2015)... , Jan. 15, 2015  BellBrook Labs, a ... discovery, announced the launch of a TR-FRET (time ... company,s Transcreener UDP Assay, a high throughput screening ... new assay will allow for sensitive detection of ...
Breaking Biology News(10 mins):Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Valid USA Signs Contract For Washington Driver's License Issuance 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... Medical Institute researchers and their colleagues have discovered a ... a cancer-causing virus found in mice. Their findings describe ... retrovirus that is native to rodents. , The researchers ... of prostate cancer. The patients in the study have ...
... announce today that gibbons, arboreal primates that inhabit the jungles ... that is present in the genomes of all other primates, ... event that occurred approximately 25 million years ago. Their ... journal Genome Research . , Agouti signaling protein ( ...
... novel genes within the tumors of women with early stage ... are not at risk for early relapse or cancer-related death. ... 1 issue of Clinical Cancer Research. , "The HOXB13 and ... of relapse in hormone-receptor positive breast cancer treated with tamoxifen," ...
Cached Biology News:New human retrovirus originated in mice 2New human retrovirus originated in mice 3New human retrovirus originated in mice 4Major obesity gene is 'lost in the shuffle' 2Mayo Clinic study finds two genes predict outcome for breast cancer patients 2
Mouse polyclonal antibody to BTG2 - BTG family, member 2...
These 96-well 0.2 ml thin-wall PCR plate caps are caps that are used to seal 96-well, 0.2 ml thin-wall PCR plates. Supplied as 300 caps....
... Source of colony stimulating factors for assays ... spleen, blood and fetal liver. Suitable ... CFU-G and CFU-GEMM when added to methylcellulose ... addition of erythropoietin. Will also support ...
... bromide), 50mg/vial. MTT is a pale yellow ... to yield a dark blue formazan product. ... freshly dead cells do not cleave significant ... component of Chemicons MTT assay kit, Catalog ...
Biology Products: